Key result
KCa3.1 ion-channel blockers (TRAM-34 and ICA-17043) markedly inhibited human fibrocyte migration in transwell assays without affecting growth, apoptosis, or differentiation.
Why the study?
Do KCa3.1 ion-channel blockers inhibit migration of human fibrocytes cultured from healthy subjects and asthmatic patients?
Do KCa3.1 ion-channel blockers inhibit migration of human fibrocytes cultured from healthy subjects and asthmatic patients?
KCa3.1 channel blockers inhibit human fibrocyte migration, highlighting a potential therapeutic target for diseases characterized by tissue fibrosis and remodeling such as asthma and idiopathic pulmonary fibrosis.
No takes yet. Share an insight, caveat, or question.
KCa3.1 blockade should not yet change practice; leaves open whether it attenuates fibrotic remodeling in asthma or IPF.
Cruse et al. (2011) studied Asthma. KCa3.1 ion-channel blockers (TRAM-34 and ICA-17043) vs. Control conditions was evaluated on Fibrocyte migration, proliferation, apoptosis, and differentiation. KCa3.1 ion-channel blockers (TRAM-34 and ICA-17043) markedly inhibited human fibrocyte migration in transwell assays without affecting growth, apoptosis, or differentiation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: